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Abstract 
Background: Malaria elimination requires reducing both the potential of mosquitoes to transmit parasites to 
humans and humans to transmit parasites to mosquitoes. To achieve this goal in Southern province, Zambia a mass 
test and treat (MTAT) campaign was conducted from 2011–2013 to complement high coverage of long-lasting 
insecticide-treated nets (LLIN). To identify factors likely to increase campaign effectiveness, a modelling approach 
was applied to investigate the simulated effect of alternative operational strategies for parasite clearance in southern 
province.
Methods: OpenMalaria, a discrete-time, individual-based stochastic model of malaria, was parameterized for the 
study area to simulate anti-malarial drug administration for interruption of transmission. Simulations were run for sce-
narios with a range of artemisinin-combination therapies, proportion of the population reached by the campaign, tar-
geted age groups, time between campaign rounds, Plasmodium falciparum test protocols, and the addition of drugs 
aimed at preventing onward transmission. A sensitivity analysis was conducted to assess uncertainty of simulation 
results. Scenarios were evaluated based on the reduction in all-age parasite prevalence during the peak transmission 
month one year following the campaign, compared to the currently-implemented strategy of MTAT 19 % population 
coverage at pilot and 40 % coverage during the first year of implementation in the presence of 56 % LLIN use and 
18 % indoor residual spray coverage.
Results: Simulation results suggest the most important determinant of success in reducing prevalence is the popula-
tion coverage achieved in the campaign, which would require more than 1 year of campaign implementation for 
elimination. The inclusion of single low-dose primaquine, which acts as a gametocytocide, or ivermectin, which acts 
as an endectocide, to the drug regimen did not further reduce parasite prevalence one year following the campaign 
compared to the currently-implemented strategy. Simulation results indicate a high proportion of low-density infec-
tions were missed by rapid diagnostic tests that would be treated and cleared with mass drug administration (MDA).
Conclusions: The optimal implementation strategy for MTAT or MDA will vary by background level of prevalence, by 
rate of infections imported to the area, and by ability to operationally achieve high population coverage. Overall suc-
cess with new parasite clearance strategies depends on continued coverage of vector control interventions to ensure 
sustained gains in reduction of disease burden.
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Background
Malaria elimination requires reducing both the poten-
tial of mosquitoes to transmit parasites to humans and 
humans to transmit parasites to mosquitoes, including 
reaching humans with asymptomatic infections. With the 
backdrop of several years of high coverage of long-lasting 
insecticide-treated mosquito nets (LLINs), many coun-
tries are looking to reorient their malaria programmes 
from control to elimination, including the adoption of 
additional strategies for programme implementation and 
surveillance.
Zambia has a long history of malaria control efforts 
dating back to the 1920s with the mining sector in the 
copperbelt [1]. With the advent of the Roll Back Malaria 
initiative in 1998, Zambia began to introduce additional 
insecticide-treated bed nets (ITNs) as part of small-scale 
delivery programmes targeting vulnerable populations. 
Following initiation of malaria funding from the Global 
Fund for AIDS, Tuberculosis and Malaria and other part-
ners, a scaling up of key malaria interventions, including 
mass distribution of ITNs, renewed efforts to increase 
IRS coverage, artemisinin-combination therapy (ACT) 
for anti-malarial treatment, and rapid diagnostic tests for 
case management began to reach communities by 2005. 
This scaling up for impact (SUFI) approach contributed 
to an observed 63 % decrease in Plasmodium falciparum 
prevalence in ages 2–9 and a 22  % decrease in malaria 
deaths [2]. In response to the need to plan next steps to 
accelerate the goal of malaria elimination the Zambia 
national malaria control centre (NMCC) in partnership 
with PATH MACEPA is conducting an evaluation of 
strategies for anti-malarial drug campaigns. These strate-
gies are designed to complement the existing high cover-
age of vector control interventions and aim to contribute 
to a marked reduction of community level malaria. In 
addition to the 2011–2013 implementation strategy of 
mass test and treat (MTAT) targeting all ages with three 
rounds of artemether-lumefantrine (AL) [3] an additional 
set of operational and chemotherapeutic options are cur-
rently under evaluation [4]. These changes to the design 
include replacing AL with another ACT, dihydroarte-
misinin  +  piperaquine (DHAP), which clears asexual 
blood stages of current infections and has a longer pro-
phylactic period against future malaria infection [5], as 
well as use of single low-dose (SLD) primaquine [6] and/
or ivermectin [7] to stop onward transmission to humans.
Primaquine is a gametocytocidal drug that reduces 
the duration of late-stage P. falciparum gametocytes, 
the transmissible stage of the parasite from human to 
mosquito, and therefore has the potential to reduce 
malaria transmission [8]. The World Health Organiza-
tion (WHO) currently recommends the use of SLD pri-
maquine in addition to an ACT for all patients with 
parasitologically-confirmed P. falciparum malaria to aid 
in malaria elimination and to contain the spread of arte-
misinin resistance [9]. However, this use of primaquine is 
not currently widespread due to the limited availability 
of appropriate dosing regimens for young children and 
some residual confusion regarding the safety of SLD 
versus standard higher dosing of primaquine in patients 
with glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency. Clinical trials to determine the lowest possible 
dose effective at clearing gametocytes are in process in 
a number of locations considering the inclusion of the 
drug in elimination strategies including Uganda [10], The 
Gambia [11], and Mali [12].
Ivermectin is an anthelmintic drug currently used for 
control of onchocerciasis and lymphatic filariasis. It also 
has endectocidal properties reducing the sporogony [13] 
and survivorship [14] of mosquitoes that take a blood 
meal from humans with the drug in their system. Stud-
ies indicate that mass drug administration (MDA) with 
ivermectin has the potential to assist in the interruption 
of malaria transmission [15, 16], and has the potential to 
combine malaria elimination efforts with other helminth-
based diseases considered for elimination.
OpenMalaria is a stochastic individual-based model 
of malaria that has been used to address questions rel-
evant to malaria epidemiology, vaccine development [17], 
cost-effectiveness of different combinations of malaria 
control interventions [18], and vector control technolo-
gies [19]. In order to assist the National Malaria Control 
Programme and implementing partners in Zambia with 
model-based guidance on community-based treatment 
strategies, OpenMalaria was employed to simulate the 
effectiveness of changing the operational strategy of the 
malaria testing and treatment campaign. This paper pre-
sents the simulation results of MTAT with AL, MTAT 
with DHAP (with or without ivermectin), and MDA 
with DHAP (with or without ivermectin and/or SLD 
primaquine).
Methods
OpenMalaria model
Alternative strategies and drug interventions against 
malaria parasites and the mosquito vector were evalu-
ated using OpenMalaria. OpenMalaria combines sto-
chastic individual-based simulation models for malaria in 
humans with a periodically-forced deterministic model 
for malaria in mosquitoes [20–23]. The models have 
been fitted to multiple field data sets and the models for 
malaria in humans include demography, acquired immu-
nity and super-infection, variations in parasite densities 
and infectiousness to mosquitoes and the clinical effects 
of malaria. The model for malaria in mosquitoes includes 
multiple mosquito species, varying vector behaviour and 
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non-human hosts [20–23]. The model platform consists 
of an ensemble of fourteen model variants that allow 
different assumptions such as heterogeneity in expo-
sure and decay of immunity to help quantify the effects 
of uncertainty in model formulation [23]. Details of the 
model and simulation set up can be found in the refer-
ences above.
Baseline scenario parameterization
The baseline scenario parameterization incorporated 
published literature and available data from field studies 
to represent the context of malaria in Zambia’s South-
ern province, where elimination strategies in the country 
were initiated. The seasonal pattern of malaria transmis-
sion corresponds to the majority of infections occur-
ring from January to May with Anopheles gambiae and 
A. funestus as the primary vectors [24, 25]. The baseline 
case management system assumes 21.8  % of fever cases 
access an anti-malarial, either the recommended first 
line anti-malarial drug (AL) introduced in 2006 [26] or 
sulfadoxine–pyrimethamine (SP), the second most com-
monly-used anti-malarial [25]. 81 % of the population is 
assumed to fully adhere to AL [27], and 39.4 % to adhere 
to SP [28]. Non-adherers to AL receive a reduced prob-
ability of clearing the infection, while all non-adherers to 
SP are assumed to not clear infections. Existing malaria 
control interventions described in Fig.  1. Coverage of 
any given intervention is assumed to be independent of 
coverage of any other intervention. Simulations assume 
71.8 % of the population in the study area own an LLIN, 
41.3  % of the population slept under a net the previous 
night [29], and 18 % of households received indoor resid-
ual spraying (IRS). Coverage of MTAT interventions were 
chosen based on the preliminary results from the MTAT 
pilot in 2011 and 2012. Overall, 19  % of the simulated 
population received an MTAT intervention in December 
2011; in each of the 2012 dry season rounds, 40 % of the 
simulated individuals received an MTAT intervention so 
that over three rounds approximately 78 % of the simu-
lated population received at least one malaria test.
This baseline scenario was simulated on a population 
of 10,000 individuals with Zambia’s population age struc-
ture [30]. Simulation results from the baseline scenario 
were validated against observed rapid diagnostic test 
(RDT) positivity rates by facility catchment area follow-
ing the scale up of the MTAT programme using AL [29]. 
Results were stratified by baseline parasite prevalence, 
taking into account variations in transmission intensity.
Experiment design and analysis
To investigate the effects of operational considerations of 
MTAT with AL on health outcomes, assuming the baseline 
MTAT implementation as illustrated in Fig. 1, the scenarios 
described in Table 1 were included in the experiment and 
altered one at a time. These include varying the age groups 
targeted by the campaign, varying the time between cam-
paign delivery rounds, and varying the proportion of the 
population reached by the campaign. MTAT campaign 
coverage numbers were chosen to correspond to the pre-
liminary findings of coverage achieved by the 2011–2012 
intervention implementation. Age groups were chosen 
to correspond to the groups with the highest parasite 
Fig. 1 Schematic of malaria control interventions existing in Southern province, Zambia from 2006 to 2012 that served to inform the baseline sce-
nario used for this experiment. The blue circles correspond to months with no active deployment of malaria control interventions. The green circles 
corresponds to months where vector control interventions were deployed and the open red circles correspond to months were drug interventions 
were deployed
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prevalence rates. To investigate the effects of changing 
the drug regimen on health outcomes of the MTAT inter-
vention, scenarios were simulated with the longer-acting 
DHAP, both alone and paired with ivermectin (Table  2). 
To investigate the effects of removing the RDT and imple-
menting an MDA campaign, scenarios were simulated with 
DHAP alone, DHAP  +  SLD primaquine, DHAP  +  iver-
mectin, and the combination of all three drugs (Table 2).
A sensitivity analysis was conducted to investigate 
the sensitivity of the intervention to changes in factors 
likely to influence the effect of the specific intervention 
or strategy. This includes the proportion of the popula-
tion who fully adhere to the AL drug regimen (Table 1), 
and the duration of the effects of ivermectin and SLD 
primaquine (Table 2). In addition, each of the scenarios 
described above were simulated over fourteen model 
variants with varied assumptions about malaria epide-
miology to account for model uncertainty [23], and three 
random seeds to account for the effects of stochasticity.
Intervention scenarios were evaluated based on the 
simulated reduction in mean all-age parasite prevalence 
taken over the 14 model variants and three random seeds 
(mean parasite prevalence) in the peak month of malaria 
transmission one year following the intervention com-
pared to the baseline scenario.
Intervention assumptions
Drugs
AL is assumed to clear 100 % of asexual blood stage infec-
tions [31] in individuals with full adherence to the drug 
regimen with a prophylactic period of 25 days [32]. DHAP 
is assumed to have an equivalent effect on clearing exist-
ing asexual blood stage infections as AL, but goes on to 
have a prophylaxis benefit for an additional 10 days [32] 
during which new infective mosquito bites do not go on 
to transmit infection. Ivermectin is given as a single dose 
with an 85 % killing effect on mosquitoes; killing time is 
varied to be either 2, 4 or 7  days according to the dose. 
Primaquine is given as a single low dose formulation and 
is assumed to immediately kill all sexual stage 5 parasites 
with a half-life of 2  days. However, all remaining earlier 
stage parasites and those arising from an incompletely 
cleared infection become stage 5 parasites and are able to 
be transmitted. Adherence rate for both AL and DHAP 
is assumed to be 75  % in the baseline simulations but 
is varied in the sensitivity analysis as described above. 
Because missing the final dose has been reported to be 
the most common reason for non-adherence [33] leading 
to a lower mean plasma lumefantrine level in individuals 
treated with AL [34], the probability of infection clearance 
is reduced by 15 % for non-adherers. Adherence to SLD 
primaquine and ivermectin is assumed to be 100 % given 
their administration at the start of the drug regimen and 
therefore likelihood of direct observation. Assumptions 
about the decay of effectiveness of the range of drugs sim-
ulated in this experiment are summarized in Fig. 2.
Delivery method
With MTAT implementation, an ACT is only given 
to individuals with a positive RDT result; thus, the 
Table 1 Experiment design for mass test and treat (MTAT) with artemether-lumefantrine (AL)
Baseline values indicated in italics
Variable Simulation levels
Target ages receiving the campaign All ages, children under 5, children 5–14, adults 25–49
Time between MTAT delivery rounds (total of three rounds) 2, 3, 4, 8 weeks
Proportion of the population reached per round by the MTAT campaign 0, 40, 72, 100 %
Proportion of the population who fully adhere to the AL drug regimen 50, 75, 100 %
Table 2 Experiment design for campaign implementation with dihydroartemisinin–piperaquine (DHAP)
Baseline values indicated in italics
a In this scenario ivermectin is given to every individual reached by the campaign, regardless of the result of their malaria test
Drug combination Population reached 
by MTAT campaign
Population reached  
by MDA campaign
Ivermectin duration 
of effectiveness
Single low-dose (SLD) 
primaquine half-life
Campaign implementation  
with DHAP
40, 72 % 40, 72 %
DHAP + ivermectin 40, 72 %a 40, 72 % 2, 4, 7 days
DHAP + SLD primaquine 40, 72 % 12, 48, 72 h
DHAP + ivermectin + SLD pri-
maquine
40, 72 %
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sensitivity and specificity of the RDT establish the likely 
proportion of which individuals will test positive accord-
ing to parasite density of the infection, and which indi-
viduals will be infected but test negative. These will 
typically be individuals with lower parasite density who 
may also have a lower likelihood of transmitting to mos-
quitoes. In scenarios including ivermectin with MTAT, 
while ACT is only given to individuals who test posi-
tive, ivermectin is given to every individual reached by 
the campaign, regardless of the result of their malaria 
test. This is because ivermectin is not a therapeutic drug 
for malaria treatment, but rather acts as an endectocide 
that is toxic to mosquitoes that bite an individual with 
the drug in their system. With MDA implementation, 
the drugs are given to everyone. However, this is moder-
ated by the population coverage of the intervention; some 
people are reached and others are not, and an individual 
has the same independent likelihood of receiving the 
intervention in each delivery round.
Vector control
LLIN deterrency and pre- and post-prandial killing of 
malaria vector mosquitoes were parameterized using 
experimental hut data, as described in Briët et  al. [19]. 
LLINs are assumed to decay over time at different rates 
for their physical state, chemical state, and attrition from 
circulation. IRS deterrency and post-prandial killing are 
assumed to decay over time with an exponential func-
tion and a half-life of 4 months. Both LLINs and IRS are 
assumed to only affect the proportion of indoor biting 
and resting mosquitoes. Additional details of the model 
description and parameterization of vector control inter-
ventions are described elsewhere [19, 35].
Results
MTAT with AL strategy used in 2011–2013
The model was able to simulate the range of observed 
prevalence of health facility catchment areas at each of 
the three MTAT deployment rounds in each of the three 
parasite prevalence strata at the time of the December 
2011 pilot survey (Fig.  3). Both the observed and simu-
lated data show the variance in prevalence between 
health facility catchment areas decreasing through the 
season. However, for the health facility catchment areas 
representing the highest parasite prevalence rate, the 
simulation runs under-estimated the peak parasite preva-
lence rate (no estimates were greater than 35 %) for the 
June/July intervention round when the observed preva-
lence rates reached as high as 48  % (Fig.  3) [28]. This 
trend was also observed in subsequent intervention 
rounds (Fig. 3).
Results suggest a substantial proportion of infections in 
the population exist with parasite densities of fewer than 
100 parasites per microlitre, the RDT detection limit 
assumed by the model. Simulations indicate the median 
proportion of infections that are sub patent is 20  % in 
scenarios with a baseline of less than 10 % mean parasite 
prevalence at the 2011 survey, dropping to 10 % in sce-
narios with baseline mean parasite prevalence in the two 
higher prevalence categories (Fig. 4).
Fig. 2 Assumptions about the decay in drug effectiveness. ACT (dashed/dotted lines) decay in a step-wise fashion with AL (green) lasting 25 days 
and DHAP (purple) 35 days. PQ (solid line) has an exponential decay with varying half-life of effectiveness of 12 (gray), 48 (blue), and 72 h (orange). 
Ivermectin (dashed lines) smoothly decays to efficacy of zero after 2 (red), 4 (grey), and 7 days (brown)
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Changing operational strategy of MTAT campaign
Changes in the proportion of the population reached by 
the campaign, the number of days between screen and 
treat rounds, and varying the anti-malarial drug used 
in the campaign had the greatest effect in areas with a 
starting mean parasite prevalence of greater than 24  %, 
and the least effect in areas with a starting mean para-
site prevalence of less than 10  % (Fig.  5). A contribut-
ing factor to this effect could be the greater variation in 
simulated results in this lowest-prevalence category. For 
example, when simulating the parasite prevalence given 
72 % coverage of MTAT with AL, the standard deviation 
for the <10 versus >24 % prevalence groups were ±62.5 
and ±13.8, respectively (Table 3; Fig. 5).
Targeting specific age groups for the MTAT interven-
tion, as opposed to reaching all-ages as in the current 
MTAT strategy, resulted in an increase in prevalence 
(reduced efficacy) in all prevalence categories. This 
is because a smaller proportion of the population is 
reached, even though this proportion of the popula-
tion may have a higher mean parasite prevalence. Unlike 
other operational strategy changes, changing the time 
between campaign rounds to 30  days or less showed a 
greater simulated benefit (reduction of mean parasite 
prevalence) in the higher-prevalence areas, although this 
benefit decreases as the prevalence level in the popula-
tion decreases.
From MTAT to MDA
Simulation results suggest that the most important deter-
minant of success in reducing prevalence is campaign 
coverage (Fig.  5; Table  3), with a greater effect in areas 
of higher all-age parasite prevalence. However, in these 
simulated scenarios, even when achieving high coverage 
with MDA in areas with a pre-intervention all-age para-
site prevalence of less than 10  %, complete elimination 
will require more than 1 year of campaign implementa-
tion. Indeed, preliminary findings from the Southern 
province MDA intervention trials suggest these strategies 
are able to reduce parasite prevalence in areas of 8–0.5 %; 
not elimination, but close enough to warrant moving on 
to surveillance-based interventions.
Changing drug
Changing the intervention drug to DHAP did not result 
in a simulated reduction in mean parasite prevalence 
when compared to simulated results using AL. When 
compared to implementation with AL, adding either SLD 
primaquine or ivermectin to DHAP did not result in fur-
ther simulated reduction of mean parasite prevalence 
1  year after intervention implementation in either the 
MTAT or MDA delivery strategies (Fig. 6; Table 4). 
Sensitivity analysis
Altering the proportion of the population adhering to the 
drug regimen, altering the half-life of PQ, and altering the 
duration of effectiveness of ivermectin did not contribute 
greatly to the overall uncertainty in model predictions 
(Fig. 7). The range seen in simulation results are therefore 
more likely to be due to stochasticity and model uncer-
tainty rather than variations in drug half-life/duration of 
effectiveness or adherence.
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Fig. 3 Validation of the baseline scenario parameterization: simu-
lated versus observed effect of three rounds of MTAT using AL, by 
parasite prevalence at pilot conducted in December 2011 [29]. Black 
circles represent observed all-age mean parasite prevalence rates in 
health facility catchment areas. Grey circles represent simulated mean 
parasite prevalence rates
Fig. 4 Prevalence of subpatent infections. The percentage of simu-
lated infections in the population with parasitaemia of fewer than 100 
parasites per microlitre, the simulated detection limit of the RDT used 
in the MTAT campaign. White lines represent the simulated median 
value, green boxes represent the inter-quartile range, and capped bars 
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using an ensemble of 14 model variants and three random seeds for 
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Discussion
In an era where vector control strategies have been able 
to greatly reduce disease burden across the malaria 
endemic world, many countries are now evaluating how 
to transition programmes from control to elimination. 
Mass distribution of anti-malarials, with or without a 
diagnostic, are under consideration in many settings to 
markedly reduce the human parasite reservoir to allow a 
shift to case detection via surveillance as an intervention. 
Results of this study are consistent with both modelling 
and empirical evidence that has shown implementation 
of drug-based strategies to be effective within a trans-
mission season in settings where sufficient coverage of 
the population can be achieved [36]. Yet, recent stud-
ies on screen and treat for strategies targeting the whole 
community [37] and specific risk groups [38] have been 
unable to show sustained impact. This study examined 
how the OpenMalaria platform, parameterized according 
to the malaria transmissions dynamics in southern Zam-
bia, can assist the Zambia NMCC to increase the effec-
tiveness of these planned interventions through changes 
in implementation design.
Results suggest the optimal implementation strategy 
for deployment of community-based anti-malarial treat-
ments requires a consistent approach addressing the var-
iation in baseline malaria prevalence, rate of imported 
infections, and the achievement of high coverage in the 
population. Simulations conducted for this study suggest 
that an area such as Southern province with heterogene-
ous transmission and an uncertain infection importation 
-1
00
0
10
0
20
0
30
0
<
 1
0%
 s
ta
rt
in
g 
pr
ev
al
en
ce
Coverage
-1
00
0
10
0
20
0
30
0
Time between rounds
-1
00
0
10
0
20
0
30
0
Target ages
-1
00
0
10
0
20
0
30
0
Change drug to DHAP
-1
00
0
10
0
20
0
30
0
10
 -
 2
4%
 s
ta
rt
in
g 
pr
ev
al
en
ce
-1
00
0
10
0
20
0
30
0
-1
00
0
10
0
20
0
30
0
-1
00
0
10
0
20
0
30
0
-1
00
0
10
0
20
0
30
0
>
 2
4%
 s
ta
rt
in
g 
pr
ev
al
en
ce
0% 72% 100%
-1
00
0
10
0
20
0
30
0
15 days 20 days 30 days
-1
00
0
10
0
20
0
30
0
25 - 49 under 5 5 - 14
-1
00
0
10
0
20
0
30
0
DHAP 40% DHAP 72%%
 c
ha
ng
e 
in
 a
ll-
ag
e 
pa
ra
si
te
 p
re
va
le
nc
e 
co
m
pa
re
d 
to
 e
xi
st
in
g 
st
ra
te
gy
Fig. 5 Results of changing operational strategy for mass test and treat using artemether-lumefantrine. Change (%) in the simulated mean parasite 
prevalence compared to the simulated mean parasite prevalence measured 1 year after implementation of the existing intervention strategy, 
as a result of varying the operational strategy of the intervention. Categories represented in the columns include the proportion of the popula-
tion reached by the campaign (coverage), the number of days between screen and treat rounds (time between rounds), the ages reached by the 
intervention (target ages), and varying the anti-malarial drug used in the campaign (change drug to DHAP). The existing strategy consists of three 
rounds of mass test and treat with AL covering 40 % per round of all ages in the population with 60 days between treatment rounds. The rows 
represent results stratified by the pre-intervention mean parasite prevalence in the population as measured by RDT. Centre solid lines represent the 
simulated median value, blue boxes represent the inter-quartile range, and capped bars represent the upper and lower adjacent values for simulated 
results using an ensemble of 14 model variants and three random seeds
Page 8 of 14Stuckey et al. Malar J  (2016) 15:148 
Ta
bl
e 
3 
Eff
ec
t o
f c
ha
ng
in
g 
op
er
at
io
na
l s
tr
at
eg
y 
co
m
pa
re
d 
to
 a
 b
as
el
in
e 
st
ra
te
gy
 o
f t
hr
ee
 ro
un
ds
 m
as
s 
te
st
 a
nd
 tr
ea
t w
it
h 
ar
te
m
et
he
r-
lu
m
ef
an
tr
in
e 
at
 4
0 
%
 c
ov
-
er
ag
e 
pe
r r
ou
nd
 o
f a
ll 
ag
es
 o
f t
he
 p
op
ul
at
io
n 
w
it
h 
60
 d
ay
s 
be
tw
ee
n 
ro
un
ds
Ita
lic
s 
in
di
ca
te
 re
su
lts
 th
at
 p
er
fo
rm
 b
et
te
r t
ha
n 
th
e 
ba
se
lin
e 
st
ra
te
gy
%
 C
ha
ng
e 
in
 m
ed
ia
n 
pa
ra
si
te
 p
re
va
le
nc
e 
(IQ
R)
, b
y 
pr
e-
in
te
rv
en
tio
n 
m
ea
n 
pa
ra
si
te
 p
re
va
le
nc
e
%
Co
ve
ra
ge
 (%
)
Fr
eq
ue
nc
y 
(d
ay
s)
A
ge
s
Ch
an
ge
 d
ru
g 
(%
)
0
72
10
0
15
20
30
U
nd
er
 5
5–
14
25
–4
9
D
H
A
P 
40
D
H
A
P 
72
<
10
0.
0
(−
23
.7
, 1
07
.4
)
−6
.1
(−
32
.6
, 4
4.
7)
−8
.7
(−
31
.6
, 4
3.
4)
0 (−
28
.9
, 5
6.
3)
−2
.4
(−
30
.0
, 4
2.
6)
−2
.9
(−
26
.3
, 4
8.
9)
5.
5
(−
24
.7
, 1
12
.6
)
7.
4
(−
23
.2
, 8
6.
1)
5.
8
(−
23
.9
, 1
11
.3
)
1.
6
(−
28
.9
, 6
4.
2)
−5
.5
(−
30
.0
, 4
3.
2)
10
–2
4
65
.8
(1
7.
5,
 1
07
.1
)
−1
9.
7
(−
38
.8
, −
1.
0)
−3
7.
6
(−
53
.2
, −
17
.8
)
−1
5.
1
(−
32
.5
, 6
.7
)
−1
8.
6
(−
43
.2
, −
4.
4)
−2
6.
2
(−
40
.8
, −
2.
8)
60
.8
(2
0.
6,
 9
5.
2)
43
.9
(4
.1
, 8
4.
4)
40
.9
(−
2.
9,
 7
4.
3)
−0
.8
(−
20
.1
, 2
8.
1)
−2
5.
5
(−
41
.4
, −
7.
4)
>
24
47
.5
(4
2.
7,
 5
6.
3)
−2
5.
6
(−
33
.1
, −
16
.8
)
−4
4.
2
(−
49
.9
, −
36
.6
)
−1
8.
2
(−
27
.5
, −
11
.1
)
−2
1.
4
(−
31
.8
, −
13
.6
)
−2
5.
3
(−
33
.3
, −
17
.2
)
46
.3
(3
7.
2,
 5
1.
34
)
36
.8
(2
9.
1,
 4
9.
7)
29
.8
(1
9.
4,
 3
8.
1)
2.
9
(−
3.
1,
 9
.8
)
−2
5.
7
(−
34
.5
, −
17
.2
)
Page 9 of 14Stuckey et al. Malar J  (2016) 15:148 
rate, drug-based interventions based on detecting infec-
tions using current RDTs will not be sufficient to inter-
rupt transmission. Indeed, as observed in the field study, 
there was no difference detected at follow-up in parasite 
prevalence between MTAT intervention and control in 
either high or low transmission areas [3]. In this set-
ting, a high proportion of low-density infections will be 
missed by RDTs that would be treated and cleared with 
MDA.
Simulation results suggest the most important deter-
minant of success in reducing prevalence is the cover-
age of the population achieved in the campaign. The 
Southern province field study was designed to show how 
much impact would be achieved after 1  year of cam-
paign implementation in order to move towards surveil-
lance as an intervention by focal MDA (fMDA) and case 
investigation. However, even with high coverage with 
MDA in areas with a pre-intervention all-age parasite 
prevalence of less than 10  %, simulations suggest that 
elimination will require more than 1  year of campaign 
implementation. The inclusion of SLD primaquine (a 
gametocytocide), and ivermectin (an endectocide), to the 
drug regimen did not further reduce parasite prevalence 
within this 1 year post-campaign. It is important to note 
that mean parasite prevalence measured at earlier time 
points will yield different results, as the greatest effects 
will be seen several months post-campaign. Simulation of 
ACT regimens in a generic setting have been investigated 
elsewhere, both with and without the option of including 
SLD primaquine and/or ivermectin [39, 40]. The simula-
tion results presented here are less optimistic about the 
additional added benefit of PQ and ivermectin in inter-
rupting transmission, although, importantly, the results 
are evaluated at different time points.
Success of anti-malarial drug administration campaigns 
depends on the sustained high coverage of vector control 
interventions. Zambia has been able to achieve high rates 
of household LLIN ownership and has steadily increased 
its within-household availability of LLINs through suc-
cessive mass distribution campaigns. However, LLINs 
must be used or at least deployed in the household for 
their full impact to be attributable. Improving simula-
tion estimates by including more direct measures of full 
coverage and usage of LLINs may yield greater overall 
reductions in predicted parasite prevalence in combina-
tion with the anti-malarial campaigns. Similarly with IRS, 
improved strategies to target the application of insec-
ticides could be evaluated for specific benefits. Ensur-
ing that transmitting mosquitoes are susceptible to IRS 
chemicals, that IRS is prioritized to transmission areas, 
and that full coverage of targeted areas is achieved will 
maximize the contribution of this intervention where 
drug strategies are attempted.
Fig. 6 Results of changing drug and testing protocol for anti-malarial 
drug distribution. Change (%) in the simulated mean parasite 
prevalence compared to the simulated mean parasite prevalence 
measured 1 year after implementation of a baseline strategy, for dif-
ferent combinations and testing protocols of DHAP, SLD primaquine, 
and ivermectin. Rows represent different coverage levels achieved by 
the simulated intervention. For drug combinations at 40 % coverage 
per round, the baseline includes the existing intervention strategy of 
three rounds of mass test and treat with AL covering 40 % per round 
of all ages in the population with 60 days between treatment rounds. 
For drug combinations at 72 % coverage per round, the baseline 
includes three rounds of mass test and treat with AL covering 72 % 
per round of all ages in the population with 60 days between treat-
ment rounds. Rows represent results stratified by the pre-intervention 
mean parasite prevalence in the population as measured by RDT. 
Centre solid lines represent the simulated median value, green boxes 
represent the inter-quartile range, and capped bars represent the 
upper and lower adjacent values for simulated results using an ensem-
ble of 14 model variants and three random seeds
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Planning for elimination scenarios: limitations 
and considerations
In the process of this simulation, we have identified key 
aspects of both the intervention tools and their delivery; 
improved data from the field may help in the future to 
improve the model and its ability to predict outcomes. As 
noted above, intervention coverage is a critical variable 
for these population-wide treatment efforts and inter-
vention programming should improve on the quality of 
the coverage data. For example, most coverage estimates 
only examine the coverage of the household members in 
households that were reached; a more accurate estima-
tion of the population denominator and coverage could 
perhaps be achieved by comparing satellite imaging of 
houses to actual field geo-position data of which houses 
were reached by a campaign.
Analysis was conducted with the end-point measure-
ment of reduction in parasite prevalence. This is, indeed, 
an easily-measured quantity in the field. However, future 
applications of the OpenMalaria model in the study area 
should also include an end-point measurement that 
corresponds to potential vector control interventions, 
including ivermectin. The goal of ivermectin is not to 
reduce prevalence, but to reduce transmission. Further 
analysis measuring reduction in EIR or probability of 
interrupting transmission would be a more useful way of 
evaluating the impact of this intervention. In addition to 
the clear need for direct application of field-measurable 
Fig. 7 Sensitivity analysis: artemether-lumefantrine (AL) adherence, single low dose primaquine half-life, and ivermectin duration of effectiveness. 
Change (%) in the simulated mean parasite prevalence compared to the simulated mean parasite prevalence after 1 year of implementation of a 
baseline strategy, as a result of varying the operational strategy of the intervention. Categories represented in the columns include proportion of the 
population adhering to the artemether-lumefantrine (AL) regimen, the half-life of single low dose primaquine, and duration of effectiveness at dif-
ferent coverage levels for testing strategies of ivermectin paired with AL. The rows represent results stratified by the pre-intervention mean parasite 
prevalence in the population as measured by RDT. For all categories, the baseline includes the existing intervention strategy of three rounds of mass 
test and treat with AL covering 72 % per round of all ages in the population with 60 days between treatment rounds. Baseline AL adherence is 75 %, 
baseline primaquine half-life is 48 h, and baseline ivermectin duration of effectiveness is 2 days. Centre solid lines represent the simulated median 
value, blue boxes represent the inter-quartile range, and capped bars represent the upper and lower adjacent values for simulated results using an 
ensemble of 14 model variants and three random seeds
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quantities, it would be helpful to have a standard defini-
tion for defining interruption of transmission for model 
outputs that is operationally relevant to programme set-
tings. Ideally this would include identifying the number 
of cases per week or per month in a given health facility 
catchment area that the health system would be able to 
handle.
The model has numerous limitations that are inher-
ent in the introduction of many assumptions required 
for model parameterization. For example, the modelled 
analysis included a sensitivity analysis for different levels 
of adherence to AL with the assumption that the major-
ity of non-adherers missed the final dose in the six-dose 
regimen, with results showing little impact on overall 
effectiveness. However, non-adherence would have a far 
greater impact on the cure rate of DHAP if a single dose 
of this three-dose regimen is missed [41], something not 
included in this experiment.
The field implementation targeted health facility catch-
ment areas for complete campaign coverage, while the 
simulation coverage parameterization and analysis is 
applied to the general population without explicit geo-
graphical limits. While model parameterization assumes 
an individual has the same independent likelihood of 
receiving the intervention, there are some groups that 
have a higher risk of being infected. These groups, includ-
ing adults aged 25–49 that are more highly mobile than 
the rest of the population, were targeted in the simula-
tion study design by varying the age groups targeted by 
the campaign. However, because these groups may be 
less likely to be reached during a general campaign, this 
higher risk is not captured in the baseline scenario of the 
model and may affect the impact of the simulated inter-
ventions even if a certain level of coverage is reached for 
the population as a whole.
The model parameterization assumes a conservative 
value for AL and DHAP prophylaxis based on modelling 
pharmacokinetics [41]. However, a recent publication 
of post-treatment prophylaxis of anti-malarials suggests 
both a shorter duration of protection and a greater dif-
ference between the duration of protection between AL 
and DHAP in people over 5 years of age [42]. This greater 
difference in prophylaxis benefit would affect the simu-
lation results by increasing the additional transmission 
prevented by DHAP as compared to AL.
For the ivermectin analysis, the model assumes a com-
mon effect of ivermectin no matter the age of mosquito 
post-emergence, which has been shown to be different 
in trial settings [14]. Several studies [15] have found a 
higher mortality rate in mosquitoes exposed to ivermec-
tin than the 85 % assumed in this experiment; this could 
indicate the experiment design underestimates the effect.
The model assumes a constant rate of yearly case 
importation (20 cases per 1000 individuals); this rate will 
undoubtedly vary by season and from location to location 
even within southern province, and data is not currently 
available to be able to parameterize this value correctly. 
Because the OpenMalaria simulations assumed an ongo-
ing rate of imported infections, it is not straightforward 
from model outputs to distinguish between cases arising 
from imported infections and cases that were a result of 
local transmission. This parameter is likely a key driver of 
the differences in the simulated versus observed results 
of the model validation shown in Fig. 3. If possible, future 
iterations of field work could improve the ascertainment 
of mobility and likely imported versus locally transmitted 
cases. This includes methods such as parasite genotyping 
or using human movement via mobile phone data as a 
proxy of parasite flow [43]. Understanding these dynam-
ics will aid not only in developing more relevant baseline 
model parameterization, but understanding thresholds 
for importation in a population on the effect of interven-
tion mixes. Combined with transmission estimates, these 
metrics can provide a more granular view of what inter-
vention mix to deploy, and where.
Demonstrating elimination, and evaluating the abil-
ity of interventions to interrupt transmission, requires 
metrics that are practical in operational settings. The 
reproductive number under control settings, Rc, has been 
proposed as a metric to determine whether an area has 
achieved elimination [44] by calculating the ratio of local 
cases to imported infections. However, the operational 
scale at which this should be applied is unclear, as is the 
geographical definition of infection importation in this 
context. For example, should importation from higher-
transmission zones in the same province be considered as 
part of the definition, or only importation from a neigh-
bouring country? The area in Southern province cur-
rently evaluating anti-malarial administration strategies 
is bound by the vast Lake Kariba to the east and south, 
and much lower malaria transmission areas to the north 
and west, making it an ideal setting to test elimination 
strategies. A country level metric is likely unsuitable for 
a country like Zambia which has highly heterogeneous 
endemicity in different parts of the country. On the other 
hand, applying such a metric at a more granular admin-
istrative level would not confer recognition of elimina-
tion by the WHO. Country-specific elimination strategic 
plans should address how progress will be tracked at both 
national and sub-national levels.
Other simulation studies and study data suggest the 
proportion of sub-patent infections missed by RDTs is 
higher in areas of lower transmission [37, 45, 46], consist-
ent with the simulation results from this study (Fig.  4). 
Page 13 of 14Stuckey et al. Malar J  (2016) 15:148 
Transmission due to asymptomatic infections becomes 
increasingly important (in relative terms) as cases in a 
country become fewer and national control programmes 
approach elimination and prevention of reintroduction. 
As such, further validation and calibration of models to 
the prevalence of sub-patent transmissible infections in 
different epidemiological settings needs to be conducted 
as new study data becomes available.
Finally, an important limitation for interpreting results 
is the non-spatially explicit structure of the OpenMalaria 
model. Focal test and treat and focal MDA strategies that 
involve targeting specific households, geographic areas or 
risk groups, and reactive case detection are all implemen-
tation strategies in the study area but are not evaluated 
in the context of this experiment. In addition, there are 
options for anti-malarial drug administration interven-
tion design that will be relevant in the Southern prov-
ince that are not explored in this study. Future analyses 
could examine the potential impact of this larger package 
of intervention strategies as they are implemented in the 
same or adjacent geographic areas; such analyses could 
further contribute to the future programme design by the 
NMCC.
Conclusion
The optimal strategy for implementation of community-
based interventions involving anti-malarial distribution 
will vary by background level of malaria prevalence and 
by rate of infections imported to the area. The ability to 
achieve high coverage of the population is critical to the 
success of anti-malarial distribution campaigns. This 
is reflected in the simulation results showing MDA to 
be more effective than MTAT at reducing mean para-
site prevalence 1  year after intervention implementa-
tion. While there was a simulated added benefit of the 
longer prophylactic effect of DHAP compared to AL, 
the addition of SLD primaquine and ivermectin, both 
alone and in combination, did not lead to any appreci-
able reduction in mean parasite prevalence within the 
year after implementation. Continued coverage and use 
of optimized vector control interventions is necessary 
to maximize the gains in reduction of disease burden. 
OpenMalaria can be helpful in assisting malaria control 
and elimination programmes to understand what inter-
vention strategies are most appropriate in different set-
tings, and under which conditions these strategies will 
be the most effective.
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